Peptipedia
Weight LossFDA ApprovedFDA Approved

Dulaglutide

Also known as Trulicity

An FDA-approved weekly GLP-1 receptor agonist for type 2 diabetes. Fused to an Fc antibody fragment for extended duration (~5 day half-life).

FDA Approved - Type 2 diabetes
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

1.5-4.5 mg weekly

Frequency

Once weekly

Duration

Long-term / chronic use

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 1.5-4.5 mg weekly via Subcutaneous injection weekly, Once weekly. Dose range: 0.75-4.5 mg weekly. Duration: Long-term / chronic use.

Timing & Administration

Administer via Subcutaneous injection weekly. Frequency: Once weekly.

Mechanism of Action

Two GLP-1 analogs linked to a modified human IgG4 Fc fragment extending half-life to about 5 days. Works through standard GLP-1 receptor activation.

Research Summary

Evidence level: fda approved. Clinical status: FDA Approved - Type 2 diabetes.

Side Effects & Safety

Important Warnings

  • Boxed Warning: Thyroid C-cell tumors
Nausea
diarrhea
vomiting
abdominal pain
injection site reactions
hypoglycemia
pancreatitis
gallbladder problems

References

No references available.

Related Peptides

Browse all →
SemaglutideWeight Loss

A GLP-1 receptor agonist with multiple FDA approvals including weight management, type 2 diabetes treatment, cardiovascular risk reduction, and kidney disease protection. 94% amino acid similarity to human GLP-1.

View profile
TirzepatideWeight Loss

A dual GIP/GLP-1 receptor agonist representing next-generation incretin-based therapy, demonstrating superior weight loss outcomes compared to semaglutide in direct clinical comparisons.

View profile
RetatrutideWeight Loss

A triple agonist activating GLP-1, GIP, and glucagon receptors for enhanced weight loss outcomes.

View profile